Updated: May 22, 2020
Time: Thursday, 28 May 9PM EDT
As the world's second largest funding hub for biotech, Hong Kong has unparalleled advantages for I&T in the biotech industry: internationally accredited support for drug certification which shortens the time into the Mainland market, acclaimed academia and research experts, comprehensive electronic medical data, and the one-stop support provided by HKSTP to see ideas from conception to commercialisation.
Since the pre-revenue biotech company listing regime took effect two years ago, HKEX has welcomed 16 pre-revenue biotech companies that have listed under Chapter 18A, raising a total of HK$39.7 billion. Alphamab Oncology, founded by former Boston pharmaceutical scientist Dr. Xu, was among one of them, raised $234 million and traded 35% higher from its offering price to a market cap of $1.2 billion.
With the new guidance materials for pre-revenue biotech companies recently published, this webinar aims to bring you the most updated information and relevant sharing from the key players of the ecosystem, and discuss how Hong Kong may be the place of choice to take a biotech company from startup to IPO.
Venue:Virtual Meeting – Zoom (Link to zoom webinar will be available after registration)
Pre-event & Post-event Interaction Platform: Innovation Sans Frontières on Slack
Innovation Sans Frontières (ISF) on Slack run by HKSTP is a platform for participants who are interested in Hong Kong Innovation and Technology ecosystem to stay in touch with the community, receiving the latest updates about various supports and funding opportunities in Hong Kong.
Participants can ask questions , interact with local experts, and network with other participants. All registered participants will received an invitation to join ISF slack channel. If you do not wish to receive the invitation, please email email@example.com to opt-out.
Welcome and introduction of speakers
Edward Chan, Senior Manager, Business Development, HKSTP
The New Driving Force – Connectivity
Michael Chan, Head of International Issuer Services, HKEX
From Startup to IPO: Experience sharing
Dr. Ting Xu, CEO, Alphamab Oncology
Overview of Hong Kong Biomedical Technology Landscape
Dr. Claudia Xu, CCO, HKSTP
Moderator: Xue Liang, Ph.D., Senior Scientist, Merck & Co
9:40 - 9:50 Q&A
Moderator: Edward Chan, Senior Manager, Business Development, HKSTP
9:50 - 10:30 Networking
Head of International Issuer Services | Hong Kong Exchanges and Clearing Limited (HKEX)
Mr. Michael Chan is the Head of International Issuer Services who heads the international IPO and issuer marketing efforts for HKEX. Mr. Chan is mainly focused on market development work promoting the Hong Kong listing platform and origination work attracting international and biotechnology companies to list in Hong Kong. In addition to leading the marketing efforts globally and working closely with prospects and constituents, Mr. Chan often speaks and serves as panelist and keynote speaker at major conferences and events locally and internationally. Prior to his current role, Mr. Chan has worked at the Listing Division of HKEX for 8 years covering areas of compliance, corporate governance, regulatory and IPO- related matters.
Prior to joining HKEX, Mr. Chan has worked at various financial institutions in corporate finance and business development. Michael has more than 18 years of experience in financial services and regulatory work.
Ting Xu, Ph.D.
Founder, Chairman, President & CEO | Alphamab Oncology
Dr. Xu has more than 15 years’ extensive experience in developing innovative biological drugs. Since returning to China in 2008, he has founded Suzhou Alphamab, Jiangsu Alphamab Oncology and other innovative biopharma companies, with multiple proprietary protein and antibody engineering platforms established, and built a world class biomolecular manufacturing base. Dr Xu owns or co-owns more than 100 patents and has personally led and driven the development of more than 20 innovative biological and 30 biosimilars.
Prior to Alphamab, Dr. Xu served as Senior Scientist, Senior Principal Investigator and Group Leader respectively at several global biotech companies, including Archemix, Serono and Biogen. He has comprehensive experiences and deep insights on protein engineering and antibody drug screening, and CMC, as well as pharmacology and toxicology. Several engineered protein drugs he discovered or involved in development, are already on the market or under clinical trials in Europe and the United States. Under his leadership, Alphamab Oncology is expecting to file its first NDA soon.
Dr. Xu earned his bachelor’s degree in Biochemistry from Nanjing University, and a Ph.D. from the Chinese Academy of Science, followed by postdoctoral training at Harvard University. Dr. Xu is the recipient of multiple national and regional awards, including “China Innovation & Entrepreneurship Competition – the Third Prize", "2017 Suzhou Science and Technology Innovation & Entrepreneurship – the Mayor’s Award", "Suzhou Science and Technology Figure of the Year, 2017", " Jiangsu Province’s Top 10 Scientific & Technological Innovation Entrepreneurs of the Year, 2018" and "EBC Bio-Industry Entrepreneur of the Year, 2018".
创始人、董事长、总裁兼首席执行官 | Alphamab Oncology
徐博士是南京大学生物化学学士，中科院生物物理所理学博士、哈佛大学博士后。先后荣获“中国创业大赛第三名” 、“2017年苏州市科技创新创业市长奖”、“2017年度苏州魅力科技人物” 、“2018江苏年度十大科技创新创业人物” 、“2018年EBC易贸生物产业年度企业家”等奖项。
DR. Claudia Xu
Chief Commercial Officer | HKSTP
Dr. Claudia Xu is a leader in the strategic development and commercialisation of technology, with extensive commercial, academic and consulting experience in the Asia Pacific region. She joined HKSTP in 2018 as Chief Commercial Officer to accelerate knowledge transfer and drive innovation to commercialisation. She forges strategic partnerships with key players in mainland China and international markets to attract technology companies, world class research institutes and talent to the park, and builds collaborative networks with universities, industries, professional organisations and technology companies. Before joining HKSTP, Dr. Xu was the Director of Technology Transfer Center and Chief Executive Officer of HKUST R and D Corporation Limited at the Hong Kong University of Science and Technology responsible for the University’s intellectual property management, patent portfolio development & licensing, academic-industrial collaboration, technology commercialisation and technology startup incubation, management of funding schemes supporting technology transfer and entrepreneurship. Prior to that, she worked for leading consulting firm McKinsey & Company Hong Kong, specialising in energy, chemicals and petrochemicals, and Bechtel Asia Pacific, focusing on the planning and development of large-scale infrastructure projects. Dr. Xu has a Bachelor of Engineering and Ph.D. in Chemical Engineering, and a Master of Engineering in Energy Technology.
How to become a SAPA-NE Member?
Professionals (Annual): $30
Student & Postdoc (Annual): $15
Note: Paid membership will be effective immediately after purchase.